Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nystatin + triamcinolone is a combination topical medication used chiefly to treat cutaneous fungal infections (especially infections caused by Candida species), where symptoms also include significant inflammation or itching[1][2][3][5][6][7][8][9][10]. **Nystatin** is a polyene antifungal that binds to sterols (mainly ergosterol) in fungal cell membranes, thereby altering membrane permeability and resulting in cell death[2][3][7]. **Triamcinolone acetonide** is a synthetic corticosteroid that reduces inflammation, redness, and itching by inhibiting inflammatory mediator pathways, decreasing capillary permeability, and exerting potent antipruritic and vasoconstrictive actions[2][3][7]. The combination is dispensed as a cream or ointment and is applied topically to affected skin areas, usually twice daily for no more than 25 days[1][2][3][5][7][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nystatin + triamcinolone.